BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31972634)

  • 21. Serum tumor markers and testicular germ cell tumors: a primer for radiologists.
    Marshall C; Enzerra M; Rahnemai-Azar AA; Ramaiya NH
    Abdom Radiol (NY); 2019 Mar; 44(3):1083-1090. PubMed ID: 30539249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
    Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
    J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
    Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of microRNAs in the diagnosis and monitoring of pediatric germ cell tumors: Kazakh experience.
    Saliyeva S; Boranbayeva R; Bulegenova M; Beloussov V
    Pediatr Hematol Oncol; 2024; 41(2):121-134. PubMed ID: 37898912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic Characterization of Bilateral Testicular Germ Cell Tumors With Immunohistochemical Evaluation of Mismatch Repair and
    Al-Obaidy KI; Trevino KE; Idrees MT
    Int J Surg Pathol; 2019 Sep; 27(6):619-623. PubMed ID: 30983459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
    Radtke A; Hennig F; Ikogho R; Hammel J; Anheuser P; Wülfing C; Belge G; Dieckmann KP
    Urol Int; 2018; 100(4):470-475. PubMed ID: 29698973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Refining the role of primary retroperitoneal lymph node dissection in the management of early-stage testicular cancer.
    Daneshmand S
    Curr Opin Urol; 2020 Mar; 30(2):234. PubMed ID: 31922969
    [No Abstract]   [Full Text] [Related]  

  • 28. MicroRNAs: Turning the Tide in Testicular Cancer.
    Singla N; Lafin JT; Bagrodia A
    Eur Urol; 2019 Nov; 76(5):541-542. PubMed ID: 31230742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An oncofetal and developmental perspective on testicular germ cell cancer.
    Rijlaarsdam MA; Looijenga LH
    Semin Cancer Biol; 2014 Dec; 29():59-74. PubMed ID: 25066859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives on testicular germ cell neoplasms.
    Cheng L; Lyu B; Roth LM
    Hum Pathol; 2017 Jan; 59():10-25. PubMed ID: 27569298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.
    Gillis AJ; Rijlaarsdam MA; Eini R; Dorssers LC; Biermann K; Murray MJ; Nicholson JC; Coleman N; Dieckmann KP; Belge G; Bullerdiek J; Xu T; Bernard N; Looijenga LH
    Mol Oncol; 2013 Dec; 7(6):1083-92. PubMed ID: 24012110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum tumor markers in the evaluation of male germ cell tumors.
    Barlow LJ; Badalato GM; McKiernan JM
    Nat Rev Urol; 2010 Nov; 7(11):610-7. PubMed ID: 21068762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
    Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Testicular Cancer: Diagnostics, Therapy and Follow Up].
    Kälin M; Mauti L; Pless M
    Praxis (Bern 1994); 2016 May; 105(11):643-8. PubMed ID: 27223417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.
    Leão R; Albersen M; Looijenga LHJ; Tandstad T; Kollmannsberger C; Murray MJ; Culine S; Coleman N; Belge G; Hamilton RJ; Dieckmann KP
    Eur Urol; 2021 Oct; 80(4):456-466. PubMed ID: 34175151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours.
    Pedraza AM; Stephenson AJ
    Curr Opin Urol; 2018 Sep; 28(5):448-453. PubMed ID: 29979237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large-scale study from the Cancer Registration Committee of the Japanese Urological Association.
    Kawai T; Tanaka Y;
    Int J Urol; 2017 Feb; 24(2):124-128. PubMed ID: 27915468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
    Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
    J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biology of testicular germ cell tumors.
    Vilar E; Calvo E; Tabernero J
    Clin Transl Oncol; 2006 Dec; 8(12):846-50. PubMed ID: 17169757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for stage I nonseminoma.
    Feldman DR
    J Clin Oncol; 2014 Dec; 32(34):3797-800. PubMed ID: 25366681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.